FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1990293046> ?p ?o ?g. }

• W1990293046 endingPage "672" @default.
• W1990293046 startingPage "659" @default.
• W1990293046 abstract "ObjectiveOur objective was to determine the value of frequent minimal residual disease (MRD) monitoring in acute myeloid leukemia (AML) as a robust marker of impending relapse, and whether treatment benefits patients during the MRD-positive phase of their disease.Materials and MethodsFrequent MRD monitoring was performed in all AML treatment phases using real-time quantitative polymerase chain reaction for fusion transcripts (CBFB/MYH11; RUNX1/RUNX1T1 fusion transcripts of MLL gene) and for the Wilms' tumor (WT1) gene. A total of 2,664 samples, taken from 79 AML patients and 6 healthy volunteers, were examined. Presence of fusion gene was detected in 25 of 79 examined patients.ResultsVast correlation was discovered for fusion transcripts as well as for the WT1 gene between levels in bone marrow (BM), peripheral blood, CD34+ BM cells, and CD34– BM cells. WT1 expression, however, was usually positive for cases showing fusion transcripts negativity and in healthy volunteers. Moreover, no universal value of the WT1 expression could unequivocally discriminate between remission and relapse. Therefore, detection of molecular relapses relied on fusion transcripts only and was characterized by strong expression in CD34+ cells. Considering relapsed patients, duration from molecular to hematological relapse was 8 to 79 days (median: 25.5 days). Twelve patients were treated (chemotherapy, gemtuzumab ozogamicin, or immunomodulation after allogeneic transplantation) for 21 molecular relapses and 14 responses to treatment were observed.ConclusionsFrequent quantitative monitoring of fusion transcripts is useful for reliably predicting hematological relapse in AML patients. Treatment for molecular relapse of AML can be successful. Our objective was to determine the value of frequent minimal residual disease (MRD) monitoring in acute myeloid leukemia (AML) as a robust marker of impending relapse, and whether treatment benefits patients during the MRD-positive phase of their disease. Frequent MRD monitoring was performed in all AML treatment phases using real-time quantitative polymerase chain reaction for fusion transcripts (CBFB/MYH11; RUNX1/RUNX1T1 fusion transcripts of MLL gene) and for the Wilms' tumor (WT1) gene. A total of 2,664 samples, taken from 79 AML patients and 6 healthy volunteers, were examined. Presence of fusion gene was detected in 25 of 79 examined patients. Vast correlation was discovered for fusion transcripts as well as for the WT1 gene between levels in bone marrow (BM), peripheral blood, CD34+ BM cells, and CD34– BM cells. WT1 expression, however, was usually positive for cases showing fusion transcripts negativity and in healthy volunteers. Moreover, no universal value of the WT1 expression could unequivocally discriminate between remission and relapse. Therefore, detection of molecular relapses relied on fusion transcripts only and was characterized by strong expression in CD34+ cells. Considering relapsed patients, duration from molecular to hematological relapse was 8 to 79 days (median: 25.5 days). Twelve patients were treated (chemotherapy, gemtuzumab ozogamicin, or immunomodulation after allogeneic transplantation) for 21 molecular relapses and 14 responses to treatment were observed. Frequent quantitative monitoring of fusion transcripts is useful for reliably predicting hematological relapse in AML patients. Treatment for molecular relapse of AML can be successful." @default.
• W1990293046 created "2016-06-24" @default.
• W1990293046 creator A5001656335 @default.
• W1990293046 creator A5006612295 @default.
• W1990293046 creator A5025066571 @default.
• W1990293046 creator A5028150919 @default.
• W1990293046 creator A5042672780 @default.
• W1990293046 creator A5054654885 @default.
• W1990293046 creator A5055962552 @default.
• W1990293046 creator A5063286733 @default.
• W1990293046 creator A5065520471 @default.
• W1990293046 creator A5075995955 @default.
• W1990293046 creator A5076375602 @default.
• W1990293046 date "2009-06-01" @default.
• W1990293046 modified "2023-10-02" @default.
• W1990293046 title "Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: Frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression" @default.
• W1990293046 cites W1967056296 @default.
• W1990293046 cites W1970740283 @default.
• W1990293046 cites W1976615153 @default.
• W1990293046 cites W1985165035 @default.
• W1990293046 cites W1998660089 @default.
• W1990293046 cites W2009886857 @default.
• W1990293046 cites W2021380995 @default.
• W1990293046 cites W2025645177 @default.
• W1990293046 cites W2036862498 @default.
• W1990293046 cites W2042120460 @default.
• W1990293046 cites W2061218252 @default.
• W1990293046 cites W2081386923 @default.
• W1990293046 cites W2082229999 @default.
• W1990293046 cites W2082448885 @default.
• W1990293046 cites W2087925772 @default.
• W1990293046 cites W2104073210 @default.
• W1990293046 cites W2109948637 @default.
• W1990293046 cites W2126212760 @default.
• W1990293046 cites W2128764431 @default.
• W1990293046 cites W2141324982 @default.
• W1990293046 cites W2159507916 @default.
• W1990293046 cites W2168480534 @default.
• W1990293046 cites W2318723640 @default.
• W1990293046 cites W2324104222 @default.
• W1990293046 cites W263822530 @default.
• W1990293046 cites W4376595466 @default.
• W1990293046 doi "https://doi.org/10.1016/j.exphem.2009.03.004" @default.
• W1990293046 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19463768" @default.
• W1990293046 hasPublicationYear "2009" @default.
• W1990293046 type Work @default.
• W1990293046 sameAs 1990293046 @default.
• W1990293046 citedByCount "28" @default.
• W1990293046 countsByYear W19902930462012 @default.
• W1990293046 countsByYear W19902930462014 @default.
• W1990293046 countsByYear W19902930462015 @default.
• W1990293046 countsByYear W19902930462017 @default.
• W1990293046 countsByYear W19902930462018 @default.
• W1990293046 countsByYear W19902930462019 @default.
• W1990293046 countsByYear W19902930462020 @default.
• W1990293046 countsByYear W19902930462021 @default.
• W1990293046 crossrefType "journal-article" @default.
• W1990293046 hasAuthorship W1990293046A5001656335 @default.
• W1990293046 hasAuthorship W1990293046A5006612295 @default.
• W1990293046 hasAuthorship W1990293046A5025066571 @default.
• W1990293046 hasAuthorship W1990293046A5028150919 @default.
• W1990293046 hasAuthorship W1990293046A5042672780 @default.
• W1990293046 hasAuthorship W1990293046A5054654885 @default.
• W1990293046 hasAuthorship W1990293046A5055962552 @default.
• W1990293046 hasAuthorship W1990293046A5063286733 @default.
• W1990293046 hasAuthorship W1990293046A5065520471 @default.
• W1990293046 hasAuthorship W1990293046A5075995955 @default.
• W1990293046 hasAuthorship W1990293046A5076375602 @default.
• W1990293046 hasBestOaLocation W19902930461 @default.
• W1990293046 hasConcept C10205521 @default.
• W1990293046 hasConcept C104317684 @default.
• W1990293046 hasConcept C111829193 @default.
• W1990293046 hasConcept C126322002 @default.
• W1990293046 hasConcept C143998085 @default.
• W1990293046 hasConcept C203014093 @default.
• W1990293046 hasConcept C2778274637 @default.
• W1990293046 hasConcept C2778461978 @default.
• W1990293046 hasConcept C2778729363 @default.
• W1990293046 hasConcept C2779823535 @default.
• W1990293046 hasConcept C2780007613 @default.
• W1990293046 hasConcept C28328180 @default.
• W1990293046 hasConcept C2911091166 @default.
• W1990293046 hasConcept C502942594 @default.
• W1990293046 hasConcept C54355233 @default.
• W1990293046 hasConcept C71924100 @default.
• W1990293046 hasConcept C86803240 @default.
• W1990293046 hasConceptScore W1990293046C10205521 @default.
• W1990293046 hasConceptScore W1990293046C104317684 @default.
• W1990293046 hasConceptScore W1990293046C111829193 @default.
• W1990293046 hasConceptScore W1990293046C126322002 @default.
• W1990293046 hasConceptScore W1990293046C143998085 @default.
• W1990293046 hasConceptScore W1990293046C203014093 @default.
• W1990293046 hasConceptScore W1990293046C2778274637 @default.
• W1990293046 hasConceptScore W1990293046C2778461978 @default.
• W1990293046 hasConceptScore W1990293046C2778729363 @default.
• W1990293046 hasConceptScore W1990293046C2779823535 @default.
• W1990293046 hasConceptScore W1990293046C2780007613 @default.
• W1990293046 hasConceptScore W1990293046C28328180 @default.

• next